Evidence map›Paper›PMID 38454178›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2024

Outcomes for people with TB by disease severity at presentation.

S V Leavitt, C A Rodriguez, T C Bouton, C R Horsburgh, P Abel Zur Wiesch, B E Nichols, L F White, H E Jenkins

Open access · greenAbstract read
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

S V LeavittDepartments of Biostatistics and.
C A RodriguezDepartments of Epidemiology, Boston University School of Public Health, Boston, MA.
T C BoutonSection of Infectious Diseases, Boston Medical Center, Boston, MA, Boston University School of Medicine, Boston, MA.
C R HorsburghDepartments of Biostatistics and, Departments of Epidemiology, Boston University School of Public Health, Boston, MA, Boston University School of Medicine, Boston, MA, Department of Global Health, Boston University School of Public Health, Boston, MA, USA.
P Abel Zur WieschDivision for Infection Control and Environmental Health, Norwegian Institute of Public Health, Norway;, Center of Infectious Disease Dynamics, Pennsylvania State University, Philadelphia, PA, USA.
B E NicholsDepartment of Global Health, Boston University School of Public Health, Boston, MA, USA.
L F WhiteDepartments of Biostatistics and.
H E JenkinsDepartments of Biostatistics and.
Boston University · USBoston Medical Center · USNorwegian Institute of Public Health · NO

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH · 1998 to 2026
$51.7M
Interdisciplinary Training for BiostatisticiansT32GM074905 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WHITE, LAURA FORSBERG · 2005 to 2019
$3.0M
Supplement to Methods to Estimate the Effect of Interventions on the Incidence and Transmission of TuberculosisR01GM122876 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WHITE, LAURA FORSBERG · 2017 to 2021
$1.9M
Maximizing Investigators' Research Award (R35)R35GM141821 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WHITE, LAURA FORSBERG · 2021 to 2025
$1.8M
Understanding HIV's impact on RR/MDR-TB development and transmission through genomicsK23AI152930 · NIAID · BOSTON MEDICAL CENTER · PI BOUTON, TARA CATHERINE · 2021 to 2025
$1.0M
NIAID NIH HHS K23 AI152930NIAID NIH HHS P30 AI042853NIGMS NIH HHS R01 GM122876NIGMS NIH HHS R35 GM141821NIGMS NIH HHS T32 GM074905
6 · The paper itself

Abstract

<sec id="st1"><title>BACKGROUND</title>There is substantial heterogeneity in disease presentation for individuals with TB disease, which may correlate with disease outcomes. We estimated disease outcomes by disease severity at presentation among individuals with TB during the pre-chemotherapy era.</sec><sec id="st2"><title>METHODS</title>We extracted data on people with TB enrolled between 1917 and 1948 in the USA, stratified by three disease severity categories at presentation using the U.S. National Tuberculosis Association diagnostic criteria. These criteria were based largely on radiographic findings ("minimal", "moderately advanced", and "far advanced"). We used Bayesian parametric survival analysis to model the survival distribution overall, and by disease severity and Bayesian logistic regression to estimate the severity-level specific natural recovery odds within 3 years.</sec><sec id="st3"><title>RESULTS</title>People with minimal TB at presentation had a 2% (95% CrI 0-11%) probability of TB death within 5 years vs. 40% (95% CrI 15-68) for those with far advanced disease. Individuals with minimal disease had 13.62 times the odds (95% CrI 9.87-19.10) of natural recovery within 3 years vs. those with far advanced disease.</sec><sec id="st4"><title>CONCLUSION</title>Mortality and natural recovery vary by disease severity at presentation. This supports continued work to evaluate individualized (e.g., shortened or longer) regimens based on disease severity at presentation, identified using radiography.</sec>.

Indexed as

TuberculosisBayes TheoremHumans

Identifiers

PMID38454178
PMCPMC11075045
OpenAlexW4392593036

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.